» Metabasis' Results From Its Phase 2a Clinical Trial For MB07803 For Diabetes Type 2 To Be Presented At World Congress
Metabasis Therapeutics (Nasdaq: MBRX) announced that an oral presentation summarizing the results from the Company’s Phase 2a clinical trial for MB07803 will be given at the World Congress on…